Mach7 Technologies Ltd. · ASX:M7T
Mach7 Technologies — Shareholder Meeting (November 2023)
24 slides from Mach7 Technologies's shareholder meeting presentation, Nov 16, 2023
Slide 1: 2023 Annual General Meeting Chair's & CEO's Addresses and Presentation
ASX Announcement 16 November 2023 2023 Annual General Meeting Chair’s & CEO’s Addresses and Presentation Mach7 Technologies Limited (“M7T” or “the Company”) (ASX:M7T), a company specialising in innovative imaging software solutions provides, in accordance with ASX Listing Rule 3.13.3, the attached d
Slide 2: Chair's Address
Mach7 Technologies Ltd Annual General Meeting 16 November 2023 Chair’s Address Before moving to the formal part of the meeting, I would like to provide an overview of the 2023 financial year. I will then hand over to our CEO and Managing Director Mike Lampron. For personal use only The 2023 Fiscal Y
Slide 3: Chair's Address (continued)
New customers represented 55% of FY23 sales orders, creating a platform for future sales order growth in expansion, add-on, and renewal categories. They also included strategically important new customers such as Akumin, Nuvodia and St Paul’s Hospital, Hong Kong. We recognised record revenue of $30.
Slide 4: CEO and Managing Director's Address
CEO and Managing Director’s Address Good morning, everyone and I would like to add my welcome to today’s AGM. I want to take some time this morning to talk about the key elements of our business, our recent performance and outlook. Our Enterprise Imaging Platform Turning to Slide 6, what makes Mach7
Slide 5: Our Differentiators
Our Differentiators Slide 9 outlines our major differentiators. Our enterprise first strategy is a fundamental difference. We are born from the enterprise and are moving towards radiology in contrast to a lot of PACS solutions that were born in radiology and are moving to the enterprise. We believe
Slide 6: CEO's Address (continued)
technology is going to cost, how much your radiologist is going to cost, and what your margin is going to be. When we talk about enterprise imaging, you take an image from ophthalmology and store the ophthalmology study in a VNA. It is secured, physicians have access to that image, and it provides b
Slide 7: Record Sales Orders – Subscription Weighting
achieves First Productive Use, we will bill and recognise the subscription fees which include support and maintenance over the subscription period. So, when we sign a subscription deal, it will generally be around 12 months before we begin to recognise subscription revenue. As for professional servi
Slide 8: Outlook
recognised as revenue because First Productive Use is still pending. I like to see a healthy gap between CARR and ARR, which increased to $7.1m from $3.6m at the end of June 2023. This gap shows that our sales team continues to outpace our deployment team, providing us with a healthy backlog for the
Slide 9: Mach7 Technologies Ltd Annual General Meeting November 2023
For personal use only Mach7 Technologies Ltd Annual General Meeting 16 November 2023 Mach7 Technologies ASX: M7T 1
Slide 10: Chair's Address
Chair’s Address For personal use only David Chambers 2 2
Slide 11: About Mach7 Technologies (ASX:M7T)
About Mach7 Technologies (ASX:M7T) For personal use only Mach7 Technologies develops innovative image management and viewing solutions that form the core of an integrated enterprise imaging ecosystem. We give healthcare organisations the independence and flexibility to deploy our solutions according
Slide 12: FY23 Highlights
FY23 Highlights For personal use only Record Sales Orders CARR3 ARR4 (TCV)1 Record Revenue $20.6M $17.0M run rate $40.3M $30.1M +$3.6M or 21% on PCP +$2.6M or 18% on PCP +$7.1M or 21% on PCP2 +$3.0M or 11% on PCP $24.8M at July 2023 $17.7M run rate July 2023 New contracts in EBITDA (adjusted)5 NPAT
Slide 13: CEO and Managing Director's Address
CEO and Managing Director’s Address For personal use only Mike Lampron Issued 18 February 2021, approved by the Board 5 5
Slide 14: Our Solution – Enterprise Imaging Platform
Our Solution – Enterprise Imaging Platform For personal use only Enterprise Data Management Enterprise Diagnostic Viewing Workflow Orchestration Vendor Neutral Archive eUnity Enterprise Diagnostic Viewer Communication Workflow Engine Consolidate ALL Images across the enterprise Zero Footprint HT
Slide 15: Our Solution – Workflow Solutions
Our Solution – Workflow Solutions For personal use only Quality Control Enterprise Worklists Viewer Mobility Extending Radiology Tools to Enterprise Making Clinicians More Efficient Improving Clinician Collaboration Image Quality Control Provide Clinicians with Custom Worklists Allows Bedside
Slide 16: Our Solution – Flexible Worklist Utilisation
Our Solution – Flexible Worklist Utilisation For personal use only Custom 8
Slide 17: Our Differentiators
Our Differentiators For personal use only • Enterprise First Strategy • ‘Top Performer’ Product Rankings • VNA backend data management solution • Mach7’s Viewer ranked #2 by independent designed and built for entire healthcare customer survey (KLAS Research). Features network rather than the radiolo
Slide 18: Market dynamics influencing Enterprise Imaging adoption
Market dynamics influencing Enterprise Imaging adoption Factors driving demand For personal use only • Decisions increasingly driven by C-suite with emphasis on enterprise efficiency, simplified procurement and cost savings. • Growing investment across non-acute providers. Many imaging centres and a
Slide 19: Major Contract Wins
Major Contract Wins New customers expand geographic and sectoral footprint For personal use only FY23 Highlights – New Customers Buy Entire Enterprise Imaging Platform: • St. Paul’s Hospital HK - a private hospital with ~500 beds and more than 20 departments. The capital contract has TCV of $1.52M.
Slide 20: Our Revenue Model
Our Revenue Model Revenue model caters to client funding needs For personal use only Flexible revenue model allows for both subscription and capital licences, generally on 5-year terms. Equivalent Contracts: Capital Licence Subscription Licence Activity/Timing Fee Type Revenue Contribution Revenue C
Slide 21: Record Sales Orders – Subscription Weighting
Record Sales Orders – Subscription Weighting Strong growth in recurring revenue as more customers choose subscription deals For personal use only Sales Order Composition (A$M) -TCV in Constant Currency1 Sales Order by Type (A$M) - TCV in Constant Currency1 22.2 28.6 19.8 23.6 17.2 21.4 49% 58% 15.8
Slide 22: Recurring Revenue Trending Higher
Recurring Revenue Trending Higher CARR provides an indication of future ARR once First Productive Use is achieved For personal use only Recurring Revenue: CARR vs ARR (A$M) 30.0 • Contracted Annual Recurring Revenue (CARR) of $25.5M at 30 Sep 2023, up 24% on $20.6M (30 Jun 2023). 25.0 • Annual Recur
Slide 23: Outlook
Outlook For personal use only Fragmentation Complex Renewal Sales pipeline opportunities opportunities opportunities opportunities • Fragmented imaging • More complex reading • Large FY24 renewal • Largest and most market with long-time environments and remote program will provide diverse pipeline o
Slide 24: Disclaimer “forward looking” statements
Disclaimer “forward looking” statements Summary of information: This presentation contains general and background information about Mach7 Risks: An investment in M7T securities is subject to investment and other known and unknown risks, For personal use only Technologies Limited (“M7T”) activities c
Mach7 Technologies — Shareholder Meeting (November 2023) on 6ix